Jamal Rana: The LDL Cholesterol Goal Post Has Moved
Jamal Rana, Professor in the Department of Clinical Science at Kaiser Permanente Bernard J. Tyson School of Medicine, shared on LinkedIn:
”Goal post to treat LDL cholesterol has moved in patients with high risk for heart disease. Was thrilled to be part of The Wall Street Journal coverage of the biggest trials presented at AHA Scientific Sessions. We are now in era where multiple options exist to aggressively treat LDL cholesterol in high risk patients to prevent heart disease.
A PCSK9 inhibitor, evolocumab or Repatha, used on top of lipid-lowering therapy, including a high-intensity statin, significantly cuts the risk of major adverse cardiovascular events compared with placebo when used in patients without a prior history of myocardial infarction or stroke, the VESALIUS-CV study shows over a median follow-up of 4.6 years.
A single injection of a gene-edited protein was deemed productive and safe in patients with dyslipidemia that was unresponsive to lipid-lowering therapy, according to a phase I trial. IV CTX310 is an in vivo CRISPR-Cas9 gene-editing drug product targeting ANGPTL3.
CORALreef Lipids trial demonstrated that treatment with enlicitide decanoate, once-daily oral PCSK9-inhibitor, resulted in a statistically significant and clinically meaningful reduction in LDL cholestrol.”

Check here for more information.
Stay updated on all scientific advances with Hemostasis Today.
-
Feb 22, 2026, 14:16Ilenia Calcaterra: From Representation to Intellectual Independence in Women in Science
-
Feb 22, 2026, 13:27Pete Stibbs: New AHA and ACC PE Guidelines Finally Align with Real Clinical Practice
-
Feb 22, 2026, 10:39Tagreed Alkaltham: Fibrinogen Concentrate Is a Deliberate Clinical Choice in Acute Bleeding
-
Feb 22, 2026, 09:38Abdulrahman Nasiri: Significant Shifts In The 2026 AHA/ACC Guidelines for Acute Pulmonary Embolism
-
Feb 22, 2026, 09:22Shiny K. Kajal: Not All Transfusion Reactions Are Immunohematologic Incompatibilities
-
Feb 22, 2026, 09:12Arun V J։ The Hidden Risks in Every Blood Bag
-
Feb 22, 2026, 08:56Parandzem Khachatryan։ How Hard Is It to Be a Mom, a Wife, a Professor, and a Doctor All at Once?
-
Feb 22, 2026, 08:46Anirban Sen Gupta Presents Bioinspired Platelet Surrogates at MTEC
-
Feb 22, 2026, 08:31Heghine Khachatryan: Advancing Care for Women and Girls with Bleeding Disorders is A Matter of Equity